MB
MindMend Bio develops targeted therapies for neurodegenerative diseases using advanced biotechnology techniques, including gene editing and biomarker identification. The company aims to improve patient outcomes by addressing the underlying biological mechanisms of conditions such as Alzheimer's and Parkinson's disease.
Updated 4 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Product
Features
- MindMend Bio develops targeted therapies for neurodegenerative diseases using advanced biotechnology techniques, including gene editing and biomarker identification. The company aims to improve patient outcomes by addressing the underlying biological mechanisms of conditions such as Alzheimer's and Parkinson's disease.